Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Moore

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Gynecologic Oncology|November 15, 2011
Robotic-assisted surgery in gynecologic oncology: a Society of Gynecologic Oncology consensus statement. Developed by the Society of Gynecologic Oncology's Clinical Practice Robotics Task ForcePedro T Ramirez, Sarah Adams, John F Boggess, et al.
Gynecologic Oncology|March 10, 2023
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized studyKrishnansu S Tewari, Michael W Sill, Michael J Birrer, et al.
Oncology (Williston Park, N.Y.)|November 17, 2015
ACR Appropriateness Criteria® Adjuvant Therapy in Vulvar CancerShruti Jolly, Payal Soni, David K Gaffney, et al.
American Journal of Clinical Oncology|July 12, 2016
ACR Appropriateness Criteria® Management of Recurrent Endometrial CancerMohamed A Elshaikh, Sean Vance, David K Gaffney, et al.
Gynecologic Oncology|August 21, 2016
Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysisKathleen N Moore, James J Java, Katrina N Slaughter, et al.
Journal of the American College of Radiology : JACR|May 29, 2012
ACR Appropriateness Criteria® pretreatment planning of invasive cancer of the cervixCary Lynn Siegel, Rochelle F Andreotti, Higinia Rosa Cardenes, et al.
Molecular Cancer Therapeutics|August 28, 2020
Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062)Krishnansu S Tewari, Michael W Sill, Bradley J Monk, et al.
Lancet (London, England)|August 1, 2017
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)Krishnansu S Tewari, Michael W Sill, Richard T Penson, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Gynecologic Oncology|November 15, 2011
Robotic-assisted surgery in gynecologic oncology: a Society of Gynecologic Oncology consensus statement. Developed by the Society of Gynecologic Oncology's Clinical Practice Robotics Task ForcePedro T Ramirez, Sarah Adams, John F Boggess, et al.
Gynecologic Oncology|March 10, 2023
Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized studyKrishnansu S Tewari, Michael W Sill, Michael J Birrer, et al.
Oncology (Williston Park, N.Y.)|November 17, 2015
ACR Appropriateness Criteria® Adjuvant Therapy in Vulvar CancerShruti Jolly, Payal Soni, David K Gaffney, et al.
American Journal of Clinical Oncology|July 12, 2016
ACR Appropriateness Criteria® Management of Recurrent Endometrial CancerMohamed A Elshaikh, Sean Vance, David K Gaffney, et al.
Gynecologic Oncology|August 21, 2016
Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysisKathleen N Moore, James J Java, Katrina N Slaughter, et al.
Journal of the American College of Radiology : JACR|May 29, 2012
ACR Appropriateness Criteria® pretreatment planning of invasive cancer of the cervixCary Lynn Siegel, Rochelle F Andreotti, Higinia Rosa Cardenes, et al.
Molecular Cancer Therapeutics|August 28, 2020
Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062)Krishnansu S Tewari, Michael W Sill, Bradley J Monk, et al.
Lancet (London, England)|August 1, 2017
Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)Krishnansu S Tewari, Michael W Sill, Richard T Penson, et al.
Pageof 4